{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-152864","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.441585+00:00","generated_at":"2026-05-15T06:38:19.397781+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Evommune hosts webcast on MRGPRX2 inhibition for migraine treatment","bullets":["Presentation reviews migraine treatment landscape and potential role of MRGPRX2 inhibition.","No new clinical data, financial results, or regulatory milestones disclosed.","Webcast replay available on company IR website."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-152864","json":"https://secwatch.observer/filing/0001193125-26-152864.json","markdown":"https://secwatch.observer/filing/0001193125-26-152864.md","text":"https://secwatch.observer/filing/0001193125-26-152864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526152864/0001193125-26-152864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526152864/evmn-20260413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:38:19.397781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}